了解速发过敏反应及其症状
了解 9 种最常见的食物过敏原和常见的食物过敏症状
了解一些食物过敏患者的其他特应性病症
了解不同类型的食物不良反应
了解 600 mg 七种常见食物过敏原在真实世界中的食物等效量
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT
The link you have selected will take you to Genentech Clinical Trials, a different site also maintained by Genentech Medical Affairs.
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
Ab: antibody
AE: adverse event
ASTCT: American Society for Transplantation and Cellular Therapy
CR: complete response
CRS: cytokine release syndrome
CT: computed tomography
CTCAE: Common Terminology Criteria for Adverse Events
DoR: duration of response
ECOG PS: Eastern Cooperative Oncology Group performance status
FL: follicular lymphoma
ICANS: immune effector cell-associated neurotoxicity syndrome
IRF: independent review facility
IV: intravenous
IQR: interquartile range
NCI CTCAE: National Center Institute Common Terminology Criteria for Adverse Events
NHL: non-Hodgkin lymphoma
ORR: objective response rate
PET: positron emission tomography
PFS: progression-free survival
PR: partial response
R/R: relapsed/refractory
SAE: serious adverse event
SD: stable disease
USPI: United States Prescribing Information
UTI: urinary tract infection
ABC: activated B-cell–like subtype
BICR: blinded independent central review
CI: confidence interval
CNS: central nervous system
CR: complete response
DLBCL: diffuse large B-cell lymphoma
ECOG PS: Eastern Cooperative Oncology Group performance status
EFSefficacy: event-free survival for efficacy causes (time from randomization to the earliest occurrence of disease progression/relapse, death due to any cause, initiation of any non-protocol specified anti-lymphoma treatment, or biopsy-confirmed residual disease after treatment completion)
EOT: end of treatment
GCB: germinal-center B-cell–like subtype
HGBL: high-grade B-cell lymphoma
HHV8: human herpesvirus 8
HR: hazard ratio
INV: investigator
IPI: International Prognostic Index
ITT: intention-to-treat
LYSA: Lymphoma Study Association
NE: not evaluable
NOS: not otherwise specified
OS: overall survival
PET-CT: positron emission tomography and computed tomography
PFS: progression-free survival
Pola-R-CHP: polatuzumab plus rituximab, cyclophosphamide, doxorubicin, prednisone
R: randomization
R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone
R-CHP: rituximab plus cyclophosphamide, doxorubicin, prednisone
USPI: United States Prescribing Information
DBPCFC: Double-blind, placebo-controlled food challenge
FDA: Food and Drug Administration
ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
IgE: Immunoglobulin E
NIH: National Institutes of Health
OIT: Oral immunotherapy
OLE: Open-label extension
R: Randomized
CD19: Cluster of differentiation 19
CD20: Cluster of differentiation 20
CDC: Centers for Disease Control and Prevention
COVID-19: Coronavirus disease of 2019
DMT: Disease-modifying therapy
ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis
EMA: European Medicines Association
FDA: Food and Drug Administration
IgG1: Immunoglobulin G1
LMP: Last menstrual period
mAb: Monoclonal antibody
MCA: Major congenital anomalies
MS: Multiple sclerosis
OCR: OCREVUS (ocrelizumab)
RID: Relative infant dose
UCSF: University of California San Francisco
URTI: Upper respiratory tract infection
UTI: Urinary tract infection
ASTCT: American Society for Transplantation and Cellular Therapy
CD20: Cluster of differentiation 20
CR: Complete response
CRS: Cytokine release syndrome
CT: Computed tomography
CTCAE: Common Terminology Criteria for Adverse Events
DLBCL: Diffuse large B-cell lymphoma
DoCR: Duration of complete response
DoR: Duration of response
ECOG PS: Eastern Cooperative Oncology Group performance status
FL: Follicular lymphoma
HGBCL: High-grade B-cell lymphoma
ICANS: Immune effector cell-associated neurotoxicity syndrome
IRC: Independent Review Committee
NOS: Not otherwise specified
ORR: Objective response rate
PET: Positron emission tomography
PMBCL: Primary mediastinal B-cell lymphoma
AE: Adverse event
Ang2: Angiopoietin-2
ASTCT: American Society for Transplantation and Cellular Therapy
ATG: Anti-thymocyte globulin
CAR: Chimeric antigen receptor
CARTOX: CAR T-cell Therapy-Associated Toxicity
CD3: Cluster of differentiation 3
CPAP: Continuous positive airway pressure
CRP: C-reactive protein
CRS: Cytokine release syndrome
CTCAE: Common Terminology Criteria for Adverse Events
DIC: Disseminated intravascular coagulation
HLH: Hemophagocytic lymphohistiocytosis
ICANS: Immune effector cell–associated neurotoxicity syndrome
ICU: Intensive care unit
IFN-γ: Interferon-gamma
IL: Interleukin
INR: International normalized ratio
IRR: Infusion-related reaction
MAS: Macrophage activation syndrome
MSKCC: Memorial Sloan Kettering Cancer Center
NO: Nitric oxide
PTT: Partial thromboplastin time
TNF-α: Tumor necrosis factor alpha
VWF: von Wilebrand factor
CD3: Cluster of differentiation 3
TCR: T-cell receptor
CD4: Cluster of differentiation 4
CD8: Cluster of differentiation 8
CD226: Cluster of differentiation 226
Ig: Immunoglobulin
ITIM: Immunoreceptor tyrosine-based inhibitory motif
MHC: Major histocompatibility complex
NK: Natural killer
PD-1: Programmed cell death protein 1
PD-L1: Programmed death-ligand 1
PVR: Poliovirus receptor
TIGIT: T-cell immunoreceptor with Ig and ITIM domains
ARR: Annualized Relapse Rate
ART: Assisted Reproductive Technology
CI: Confidence Interval
DMT: Disease-modifying therapy
EDSS: Expanded Disability Status Scale
MS: Multiple Sclerosis
T: Trimester
OR: Odds ratio
OB/Gyn: Obstetrics and Gynecology
AAAAI: American Academy of Allergy Asthma & Immunology
DMT: Disease-modifying therapy
HCP: Health Care Provider
Ig: Immunoglobulin
LLN: Lower limit of normal
MS: Multiple Sclerosis
NK: Natural killer
FAERS: FDA Adverse Event Reporting System
FDA: US Food and Drug Administration
Ig: Immunoglobulin
LMP: last menstrual cycle
MCA: major congenital anomalies
MS: Multiple sclerosis
OCR: OCREVUS (ocrelizumab)
PML: progressive multifocal leukoencephalopathy
PPMS: Primary progressive multiple sclerosis
RMS: Relapsing multiple sclerosis
The link you have selected will take you to a separate website not owned or controlled by Genentech. Genentech does not recommend, endorse, or make any representation regarding the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.